The breakthrough in protein misfolding disorders [2/11/25]

 Protein misfolding underlies numerous genetic disorders, including Alzheimer’s disease, Parkinson’s disease, and various others. Often, a single amino acid substitution can destabilise a protein, disrupt its normal function, and compromise intracellular quality control systems. Consequently, correcting such misfolding errors constitutes a central objective in contemporary molecular medicine. 

A promising therapeutic approach involves pharmacological chaperones small molecules that bind to misfolded or unstable proteins, facilitating proper folding and restoring functional activity. Unlike broad-spectrum chemical chaperones, pharmacological chaperones exhibit specificity, frequently targeting the protein’s active site or ligand-binding domain. 

Recently, a significant advancement was reported in Nature Communications, where researchers identified a small-molecule compound functioning as a near-universal pharmacological chaperone for the vasopressin V2 receptor (V2R), a G protein-coupled receptor integral to renal water reabsorption. Mutations in the V2R gene cause X-linked nephrogenic diabetes insipidus, a disorder in which kidney cells fail to respond to antidiuretic hormone, leading to excessive water loss. 

The investigative team generated an extensive library encompassing approximately 7,000 single–amino acid variants of V2R, representing nearly all possible point mutations. They evaluated an already approved small-molecule drug, known to bind the wild-type receptor, for its capacity to rescue folding and trafficking of these mutant receptors to the cell surface. 

The findings were notable: the compound stabilised the majority of mutant V2R proteins, facilitated their maturation, and enabled proper cell surface localization. Functional assays demonstrated that many previously dysfunctional mutants regained signalling capacity. 

This study thus demonstrates that a single pharmacological chaperone can rescue a broad spectrum of mutant proteins, suggesting the feasibility of a universal therapeutic strategy applicable to multiple mutations. Such an approach holds promise for rare diseases characterised by heterogeneous mutations and limited patient populations, potentially expediting drug development. 

While further validation in animal models and clinical trials remains necessary, the identification of a nearly universal pharmacological chaperone represents a substantial advancement in precision medicine, indicating that targeting the fundamental defect of protein misfolding may supersede the need to develop mutation-specific therapies. 

 

Sources: 

• Mouillac B, Mendre C. Pharmacological chaperones as potential therapeutic strategies for misfolded mutant vasopressin receptors.  

• Liguori L, Monticelli M, Allocca M, Hay Mele B, Lukas J, Cubellis MV, Andreotti G. Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations  

• Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus M-F, Lonergan M, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.  

• Mighell TL, Toledano I, Lehner B. Mutation-agnostic stabilization of the vasopressin V2 receptor by tolvaptan.